-
Je něco špatně v tomto záznamu ?
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age
F. Baron, M. Labopin, J. Tischer, F. Ciceri, AM. Raiola, D. Blaise, S. Sica, J. Vydra, R. Fanin, F. Stölzel, A. Busca, JL. Diez-Martin, Y. Koc, A. Nagler, M. Mohty
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1998 do Před 1 rokem
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
35696192
DOI
10.1002/ajh.26627
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie * farmakoterapie MeSH
- cyklofosfamid terapeutické užití MeSH
- dospělí MeSH
- haploidentická transplantace škodlivé účinky MeSH
- HLA antigeny genetika MeSH
- kmenové buňky z periferní krve * MeSH
- kostní dřeň MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli * etiologie prevence a kontrola MeSH
- příprava pacienta k transplantaci metody MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- transplantace kostní dřeně škodlivé účinky MeSH
- transplantace periferních kmenových buněk * škodlivé účinky MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The best stem cell source for T-cell replete human leukocyte antigen (HLA)-haploidentical transplantation with post-transplant cyclophosphamide (PTCy) remains to be determined. In this European Society for Blood and Marrow Transplantation retrospective study, we analyzed the impact of stem cell source on leukemia-free survival (LFS) in adult patients with primary refractory or relapsed acute myeloid leukemia (AML) given grafts from HLA-haploidentical donors with PTCy as graft-versus-host disease (GVHD) prophylaxis. A total of 668 patients (249 bone marrow [BM] and 419 peripheral blood stem cells [PBSC] recipients) met the inclusion criteria. The use of PBSC was associated with a higher incidence of grade II-IV (HR = 1.59, p = .029) and grade III-IV (HR = 2.08, p = .013) acute GVHD. There was a statistical interaction between patient age and the impact of stem cell source for LFS (p < .01). In multivariate Cox models, among patients <55 years, the use of PBSC versus BM resulted in comparable LFS (HR = 0.82, p = .2). In contrast, in patients ≥55 years of age, the use of PBSC versus BM was associated with higher non-relapse mortality (NRM) (HR = 1.7, p = .01), lower LFS (HR = 1.37, p = .026) and lower overall survival (HR = 1.33, p = .044). In conclusions, our data suggest that in patients ≥55 years of age with active AML at HLA-haploidentical transplantation, the use of BM instead of PBSC as stem cell source results in lower NRM and better LFS. In contrast among younger patients, the use of PBSC results in at least a comparable LFS.
Bone Marrow Transplant Unit Medicana International Hospital Istanbul Istanbul Turkey
Division of Hematology Azienda Ospedaliero Universitaria di Udine Udine Italy
EBMT Paris Study Office CEREST TC Paris France
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Ospedale Policlinico San Martino Genoa Italy
IRCCS Ospedale San Raffaele University Vita Salute San Raffaele Milan Italy
Laboratory of Hematology GIGA I3 University of Liege and CHU of Liège Liege Belgium
Service d'Hématologie Clinique Hôpital Saint Antoine AP HP Paris France
Sorbonne University Paris France
SSCVD Trapianto di Cellule Staminali AOU Citta della Salute e della Scienza di Torino Torino Italy
University Hospital Dresden Medical Clinic 1 TU Dresden Dresden Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024953
- 003
- CZ-PrNML
- 005
- 20240528145809.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.26627 $2 doi
- 035 __
- $a (PubMed)35696192
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Baron, Frédéric $u Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium $1 https://orcid.org/0000000229443812
- 245 10
- $a Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age / $c F. Baron, M. Labopin, J. Tischer, F. Ciceri, AM. Raiola, D. Blaise, S. Sica, J. Vydra, R. Fanin, F. Stölzel, A. Busca, JL. Diez-Martin, Y. Koc, A. Nagler, M. Mohty
- 520 9_
- $a The best stem cell source for T-cell replete human leukocyte antigen (HLA)-haploidentical transplantation with post-transplant cyclophosphamide (PTCy) remains to be determined. In this European Society for Blood and Marrow Transplantation retrospective study, we analyzed the impact of stem cell source on leukemia-free survival (LFS) in adult patients with primary refractory or relapsed acute myeloid leukemia (AML) given grafts from HLA-haploidentical donors with PTCy as graft-versus-host disease (GVHD) prophylaxis. A total of 668 patients (249 bone marrow [BM] and 419 peripheral blood stem cells [PBSC] recipients) met the inclusion criteria. The use of PBSC was associated with a higher incidence of grade II-IV (HR = 1.59, p = .029) and grade III-IV (HR = 2.08, p = .013) acute GVHD. There was a statistical interaction between patient age and the impact of stem cell source for LFS (p < .01). In multivariate Cox models, among patients <55 years, the use of PBSC versus BM resulted in comparable LFS (HR = 0.82, p = .2). In contrast, in patients ≥55 years of age, the use of PBSC versus BM was associated with higher non-relapse mortality (NRM) (HR = 1.7, p = .01), lower LFS (HR = 1.37, p = .026) and lower overall survival (HR = 1.33, p = .044). In conclusions, our data suggest that in patients ≥55 years of age with active AML at HLA-haploidentical transplantation, the use of BM instead of PBSC as stem cell source results in lower NRM and better LFS. In contrast among younger patients, the use of PBSC results in at least a comparable LFS.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kostní dřeň $7 D001853
- 650 _2
- $a transplantace kostní dřeně $x škodlivé účinky $7 D016026
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 12
- $a nemoc štěpu proti hostiteli $x etiologie $x prevence a kontrola $7 D006086
- 650 _2
- $a HLA antigeny $x genetika $7 D006680
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $7 D015470
- 650 12
- $a transplantace periferních kmenových buněk $x škodlivé účinky $7 D036102
- 650 12
- $a kmenové buňky z periferní krve $7 D000072916
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a haploidentická transplantace $x škodlivé účinky $7 D000075442
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Labopin, Myriam $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Service d'Hématologie Clinique, Hôpital Saint-Antoine, AP-HP, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France
- 700 1_
- $a Tischer, Johanna $u Campus Grosshadern, LMU, Department of Internal Medicine III, University Hospital of Munich, Munich, Germany
- 700 1_
- $a Ciceri, Fabio $u IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
- 700 1_
- $a Raiola, Anna Maria $u IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation&Therapie Cellulaire, Département d'hématologie Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France
- 700 1_
- $a Sica, Simona $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy $u Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Fanin, Renato $u Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy
- 700 1_
- $a Stölzel, Friedrich $u University Hospital Dresden, Medical Clinic I, TU Dresden, Dresden, Germany
- 700 1_
- $a Busca, Alessandro $u SSCVD Trapianto di Cellule Staminali, AOU Citta della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Diez-Martin, Jose Luis $u Head of Hematology Department, Hospital G U Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Medicine Dpt. UCM, Madrid, Spain
- 700 1_
- $a Koc, Yener $u Bone Marrow Transplant Unit, Medicana International Hospital Istanbul, Istanbul, Turkey
- 700 1_
- $a Nagler, Arnon $u Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Ramat-Gan, Israel $1 https://orcid.org/0000000207631265
- 700 1_
- $a Mohty, Mohamad $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Service d'Hématologie Clinique, Hôpital Saint-Antoine, AP-HP, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France $7 xx0317729
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 97, č. 8 (2022), s. 1065-1074
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35696192 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20240528145806 $b ABA008
- 999 __
- $a ok $b bmc $g 1854578 $s 1176243
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 97 $c 8 $d 1065-1074 $e 20220624 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20221017
